Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. develops live biotherapeutic products and microbiome-based therapies for inflammatory, immune, infectious and gastrointestinal diseases. Company updates commonly address pipeline programs such as SER-155 for immune checkpoint inhibitor-related enterocolitis and prevention of bloodstream infections in allogeneic hematopoietic stem cell transplant patients, SER-603 for inflammatory bowel disease, and SER-428 for antimicrobial resistance and serious infections.
Recurring announcements include financial results, operational updates, research publications, scientific conference presentations, biomarker and microbiome-mechanism data, collaborations, financing and partnership activity, cost-control measures, and governance changes.
Seres Therapeutics (Nasdaq: MCRB) announced compelling results from the Phase 3 ECOSPOR III study of SER-109, a microbiome therapy for recurrent C. difficile infection (rCDI). The final 24-week data revealed a recurrence rate of 21.3% for SER-109 compared to 47.3% for placebo, showcasing a 54% relative risk reduction (p 0.001). The safety profile was comparable to placebo, reinforcing SER-109's potential as a first-in-class treatment. Clinical data will be presented during Digestive Disease Week 2021, alongside advancements in SER-287 and SER-301 for ulcerative colitis.
Seres Therapeutics, Inc. (Nasdaq: MCRB) has appointed David Arkowitz as the new Executive Vice President and Chief Financial Officer, effective June 1, 2021. Arkowitz brings over 30 years of experience in finance and operations from notable companies in the biotech sector, enhancing Seres' leadership team amid its pivotal SER-109 program approaching BLA submission. The company is focused on developing microbiome therapeutics, with SER-109 showing promise for recurrent C. difficile infection. The firm has received Breakthrough Therapy and Orphan Drug designations from the FDA.
Seres Therapeutics (MCRB) announced the presentation of early-stage clinical research at the ASCO Annual Meeting from June 4-8, 2021. The oral presentation will focus on microbiome diversity in hematopoietic stem cell transplantation, while a poster presentation will assess microbiome composition in relation to cancer treatment responses. The findings aim to enhance the understanding of microbiome therapeutics and their role in improving cancer treatment outcomes and reducing antibiotic-resistant infections.
Seres Therapeutics, Inc. (Nasdaq: MCRB) will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on May 18 at 4:15 p.m. ET. A live audio webcast can be accessed on their website under the 'Investors and News' section, with a replay available for 21 days post-event. Seres Therapeutics is pioneering microbiome therapeutics with its SER-109 program, showing promising results for recurrent C. difficile infection, and has received Breakthrough Therapy and Orphan Drug designations from the FDA. The company is also advancing programs for ulcerative colitis and gastrointestinal infections.
Seres Therapeutics (Nasdaq: MCRB) announced its participation in the virtual Digestive Disease Week (DDW) from May 21-23, 2021, showcasing its microbiome drug development. The company will present findings on investigational therapies SER-109, SER-287, and SER-301 aimed at treating recurrent Clostridioides difficile infection and ulcerative colitis. CDI poses a significant healthcare burden in the U.S., costing about $6.3 billion annually. Seres aims to address the urgent need for effective treatments, with SER-109 receiving FDA Breakthrough Therapy and Orphan Drug designations.
Seres Therapeutics (MCRB) reported a net loss of $35.5 million in Q1 2021, an increase from $19.9 million in Q1 2020. The rise in losses stemmed from increased clinical and development expenses, totaling $29.3 million in R&D for the quarter. Despite financial losses, the company continues to progress in its clinical pipeline, with the SER-287 Phase 2b study fully enrolled and results expected mid-2021, while SER-109 shows promising outcomes from its Phase 3 study. Seres ended the quarter with $272.5 million in cash and investments.
Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a conference call on May 4, 2021, at 8:30 a.m. ET to discuss its Q1 2021 results and provide a business update. The call can be accessed at 844-277-9450 (domestic) and 336-525-7139 (international) using conference ID 9967338. The company is known for its microbiome therapeutics, particularly the SER-109 program, which has received FDA's Breakthrough Therapy and Orphan Drug designations for treating recurrent C. difficile infection. Its SER-287 and SER-301 programs are also advancing through clinical trials.
Seres Therapeutics, Inc. (Nasdaq: MCRB) will have President and CEO Eric Shaff present at the Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021. The presentation will be pre-recorded and accessible on Seres' website at 8:00 a.m. ET on the same day, remaining available for 21 days. Seres is known for its groundbreaking work in microbiome therapies, including the SER-109 program, which targets recurrent C. difficile infections and has received Breakthrough Therapy designation from the FDA. The company is also advancing several other therapeutic candidates for gastrointestinal diseases.
Seres Therapeutics, (Nasdaq: MCRB), announced its participation in the 31st Annual Oppenheimer Healthcare Conference on March 16 at 9:20 a.m. ET. The company will provide a corporate overview during this event.
A live audio webcast will be accessible on Seres' website, with a replay available one hour post-event for 21 days.
Seres is recognized for its innovative microbiome therapeutics, including the SER-109 program, which has received Breakthrough Therapy designation from the FDA for treating recurrent C. difficile infection.
Seres Therapeutics (Nasdaq: MCRB) announced the voluntary discontinuation of patient enrollment in the MCGRAW study, focusing on SER-401 and nivolumab for metastatic melanoma. This decision follows challenges in enrollment amidst the COVID-19 pandemic. Although the preliminary results from 10 subjects indicated that SER-401 was safe and well-tolerated, the company will deprioritize its development. Seres aims to leverage insights from this study to advance future oncology programs and continues its research in microbiome therapeutics.